Adamas Orphaned for Parkinson Cure $ADMS $XHS

/ Healthcare / By

FDA has granted Adamas Pharmaceuticals, Inc. Orphan drug staus to the firm’s  ADS-5102 for the treatment of Levodopa-induced Dyskinesia associated with Parkinson’s disease.

View the full release here.